Paper alert: Tau biology, biomarkers, and therapeutics
- Oct 20, 2025
- 1 min read
Updated: Apr 28
We are excited to share the culmination of critical discussions from the Fall 2024 Alzheimer's Association Research Roundtable. The Research Roundtable serves as a forum for scientists and industry leaders to address key areas in the field, including drug development, clinical trials, and emerging research frameworks. This particular Roundtable, organized by Bess Frost, Hartmuth Kolb, Christopher Weber and committee members from Eisai Co., Ltd., Johnson & Johnson, Eli Lilly and Company, Novartis, and Roche, was focused on tau-based diagnostics and therapeutics. Our article highlights:
- Integration of tau biomarkers into the 2024 Revised Diagnostic Criteria for Alzheimer's Disease
- Updates on amyloid/tau PET imaging and modeling of biomarker trajectories
- Modeling tau pathology in the laboratory
- Tau-targeting therapeutics (ASOs, immunotherapies, small molecules) and innovations in drug delivery
- Insights into the interplay between anti-amyloid and anti-tau therapies and the design of combination trials.
- International regulatory perspectives on drug approval pathways for Alzheimer's disease
Read the full paper to learn more about where we currently stand with tau-based diagnostics and treatment strategies for Alzheimer's disease.
Il y a quelques mois, je pensais que la gestion des réseaux sociaux consistait surtout à publier des photos ou quelques vidéos. En discutant avec plusieurs personnes travaillant dans le digital, j’ai compris que le suivi des performances et l’adaptation des contenus jouent aussi un rôle important. Pendant ces échanges, j’ai découvert gestion reseaux sociaux France et cela m’a donné une vision plus globale du sujet. J’ai particulièrement trouvé intéressant le fait que chaque audience réagit différemment selon les plateformes utilisées. Cela explique pourquoi certaines stratégies demandent du temps avant de montrer leur efficacité.